A retrospective Swedish study published in Radiology found that three commercial AI-CAD systems could have flagged subtle breast-cancer signs on mammograms years before radiologists caught them clinically.
Xaira Therapeutics unveiled X-Cell, a virtual-cell AI model trained on the largest genome-wide perturbation dataset ever built, then pivoted from secrecy to hiring dealmakers for pharma partnerships.
Tempus AI posted a $5.64 million net profit in Q2 2026 after a $42.84 million loss a year earlier, raised full-year guidance, and moved to acquire Personalis to expand into tumor-monitoring blood tests.
The American Nurses Foundation and Hippocratic AI handed three nurse-led teams $10,000 microgrants to study AI's effect on patient safety and documentation — a grassroots counterweight to boardroom AI decisions.
The Miami startup building a ChatGPT for physicians raised $250 million in January 2026, doubling its valuation to $12 billion in a year — and it may soon raise again at $20 billion.
Roche and Recursion Pharmaceuticals advanced the first validated target from their AI partnership on August 5, 2026 — a neurodegenerative disease target mined from a microglia data map of over a trillion cultured neurons, the first of up to 40 programs under their up-to-$12-billion deal.
Sanofi and Owkin announced a five-year expansion of their AI partnership on June 5, 2026, licensing Owkin's K Pro platform to build autonomous 'biopharma agents' meant to run multi-step R&D tasks across Sanofi's drug pipeline.
Isomorphic Labs and Johnson & Johnson's Janssen unit announced a cross-modality AI drug-design collaboration on January 20, 2026, extending Isomorphic's platform beyond small molecules into biologics, peptides, and molecular glues aimed at historically undruggable targets.
Isomorphic Labs, the AlphaFold-derived drug-design spinoff of Google DeepMind, raised $2.1 billion on May 13, 2026, the second-largest biotech fundraise ever, betting investors that its AI platform can move from protein prediction to an actual clinical pipeline.
Eli Lilly signed a research and licensing deal worth up to $2.75 billion with Insilico Medicine on March 30, 2026, handing the AI-native biotech's generative drug-design platform a shot at filling Lilly's pipeline with molecules no human chemist screened.